1. Home
  2. BOLD vs IZEA Comparison

BOLD vs IZEA Comparison

Compare BOLD & IZEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BOLD
  • IZEA
  • Stock Information
  • Founded
  • BOLD 2018
  • IZEA 2006
  • Country
  • BOLD United States
  • IZEA United States
  • Employees
  • BOLD N/A
  • IZEA N/A
  • Industry
  • BOLD
  • IZEA Advertising
  • Sector
  • BOLD
  • IZEA Consumer Discretionary
  • Exchange
  • BOLD Nasdaq
  • IZEA Nasdaq
  • Market Cap
  • BOLD 30.3M
  • IZEA 29.1M
  • IPO Year
  • BOLD 2024
  • IZEA N/A
  • Fundamental
  • Price
  • BOLD $1.10
  • IZEA $2.58
  • Analyst Decision
  • BOLD Buy
  • IZEA
  • Analyst Count
  • BOLD 3
  • IZEA 0
  • Target Price
  • BOLD $4.00
  • IZEA N/A
  • AVG Volume (30 Days)
  • BOLD 362.2K
  • IZEA 38.5K
  • Earning Date
  • BOLD 08-11-2025
  • IZEA 08-13-2025
  • Dividend Yield
  • BOLD N/A
  • IZEA N/A
  • EPS Growth
  • BOLD N/A
  • IZEA N/A
  • EPS
  • BOLD N/A
  • IZEA N/A
  • Revenue
  • BOLD N/A
  • IZEA $36,896,490.00
  • Revenue This Year
  • BOLD N/A
  • IZEA $22.24
  • Revenue Next Year
  • BOLD N/A
  • IZEA N/A
  • P/E Ratio
  • BOLD N/A
  • IZEA N/A
  • Revenue Growth
  • BOLD N/A
  • IZEA 7.17
  • 52 Week Low
  • BOLD $1.00
  • IZEA $1.68
  • 52 Week High
  • BOLD $4.72
  • IZEA $3.15
  • Technical
  • Relative Strength Index (RSI)
  • BOLD N/A
  • IZEA 45.61
  • Support Level
  • BOLD N/A
  • IZEA $2.54
  • Resistance Level
  • BOLD N/A
  • IZEA $2.71
  • Average True Range (ATR)
  • BOLD 0.00
  • IZEA 0.14
  • MACD
  • BOLD 0.00
  • IZEA -0.02
  • Stochastic Oscillator
  • BOLD 0.00
  • IZEA 22.92

About BOLD Boundless Bio Inc. Common Stock

Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

About IZEA IZEA Worldwide Inc.

IZEA Worldwide Inc offers solutions that range from creator agency services to creator technologies to a marketplace that connects marketers with creators. The Company provides value through managing custom content workflow, creator search and targeting, bidding, analytics, and payment processing. The company also enables creators to monetize their content, creativity, and influence through brands and marketers. The company compensates these creators for producing content, such as long and short-form text, videos, photos, status updates, and illustrations, for marketers or distributing such content on behalf of marketers through their websites, blogs, and social media channels.

Share on Social Networks: